top of page
  • Writer's pictureSBIJI Innovation

Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs

Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the deferred closing of its Series C financing, raising an additional $27M to the $19M announced earlier this year for total proceeds of $46M.

12 views0 comments

Recent Posts

See All


bottom of page